Aranesp Gets Advisory Committee Boost As Amgen Braces For Labeling Negotiations
This article was originally published in The Pink Sheet Daily
FDA panel votes against reducing of darbepoietin alfa in patients with failing kidneys who are headed toward dialysis.
You may also be interested in...
CardioRenal Advisory Committee will discuss whether there should be a trial testing lower dosing limits in CKD patients. With sales declines a forgone conclusion regardless, Amgen hopes to avoid the expense of a complex study.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.